Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frovocimab Dose-Ranging Study in Primary Hypercholesterolemia
NCT01890967Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2013
- Primary completion
- Apr 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of frovocimab in hypercholesterolemia, sponsored by Eli Lilly and Company. Started Jun 2013; status: completed.
02
Drugs
frovocimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01890967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890967.